Study · Animal study (in vivo) · 2019
9 resultsShen X, Wang L, Xu C, Yang J, Peng R, Hu X, Wang F, Zheng H, Lao X
International immunopharmacology17 Jun 2019Cited by 4 (Europe PMC)
The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)
Text rights: Publisher copyright. Results still quote short attributed sentences.
1 result from studies that gave the peptide. No result from this study comes from people.
The half-life of parent Tα1 was 3 h.
In plain wordsPlain thymosin alpha‑1 had a short half-life of 3 hours.
n: not reported in source
Measurements
Source sentences
that of the parent molecule Tα1 (3 h).
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.
The half-life of the Tα1-mCH3 fusion protein was 47 h, substantially longer than 3 h for parent Tα1.
In plain wordsA thymosin alpha‑1 fusion protein stayed in the body much longer than plain thymosin alpha‑1.
n: not reported in source
Measurements
Source sentences
The half-life of Tα1-mCH3 (47 h) was substantially increased compared with that of the parent molecule Tα1 (3 h).
In order to improve the pharmacokinetic profile of Tα1, we linked the mutated CH3 (mCH3) fragment of IgG1 (human) to the C-terminus of Tα1 to produce a long-acting fusion protein, Tα1-mCH3.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
In vivo, mCH3 fusion retained the original biological activity of Tα1.
In plain wordsIn living animals, the fusion kept the original activity of thymosin alpha‑1.
n: not reported in source
Source sentences
In vivo studies indicated that mCH3 fusion retained the original biological activity of Tα1, and Tα1-mCH3 showed slightly better immunomodulatory effect than Ta1.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
In vivo, Tα1-mCH3 showed a slightly better immunomodulatory effect than Tα1.
In plain wordsIn living animals, the fusion protein had a slightly better immune effect than plain thymosin alpha‑1.
n: not reported in source
Source sentences
Tα1-mCH3 showed slightly better immunomodulatory effect than Ta1.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
In 4T1 and B16F10 tumor xenograft models, Tα1-mCH3 induced a greater abundance of CD4+ T-cells in tumor tissue than Tα1.
In plain wordsIn animal tumor models, the fusion protein brought more CD4+ T cells into tumors than plain thymosin alpha‑1.
n: not reported in source
4T1 and B16F10 tumor xenograft modelsSource sentences
In the 4 T1 and B16F10 tumor xenograft models, Tα1-mCH3 induced a greater abundance of CD4+ and CD8+ T-cells in tumor tissues compared with Ta1.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
In 4T1 and B16F10 tumor xenograft models, Tα1-mCH3 induced a greater abundance of CD8+ T-cells in tumor tissue than Tα1.
In plain wordsIn animal tumor models, the fusion protein brought more CD8+ T cells into tumors than plain thymosin alpha‑1.
n: not reported in source
4T1 and B16F10 tumor xenograft modelsSource sentences
In the 4 T1 and B16F10 tumor xenograft models, Tα1-mCH3 induced a greater abundance of CD4+ and CD8+ T-cells in tumor tissues compared with Ta1.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Tα1-mCH3 promoted IL-2 production more than Tα1.
In plain wordsThe fusion protein raised IL-2 more than plain thymosin alpha‑1 in animal tests.
n: not reported in source
Source sentences
Tα1-mCH3 exhibited better effect in promoting the production of IL-2 and IFN-γ compared with Tα1.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Tα1-mCH3 promoted IFN-γ production more than Tα1.
In plain wordsThe fusion protein raised IFN-γ more than plain thymosin alpha‑1 in animal tests.
n: not reported in source
Source sentences
Tα1-mCH3 exhibited better effect in promoting the production of IL-2 and IFN-γ compared with Tα1.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
In 4T1 and B16F10 tumor xenograft models, Tα1-mCH3 inhibited tumor growth more efficiently than Tα1.
In plain wordsIn animal tumor models, the fusion protein slowed tumor growth more than plain thymosin alpha‑1.
n: not reported in source
4T1 and B16F10 tumor xenograft modelsSource sentences
Therefore, Tα1-mCH3 more efficiently inhibited the growth of 4 T1 and B16F10 tumors than Tα1.
In the 4 T1 and B16F10 tumor xenograft models, Tα1-mCH3 induced a greater abundance of CD4+ and CD8+ T-cells in tumor tissues compared with Ta1.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.
Version 3Current
10 Oct 2026, 08:55 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC
Terms as the source lists them.
PepBank is a research reference. Talk to a doctor before you use any peptide.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated